Full Title
A Platform Study of RAS(ON) Inhibitors in Patients with Gastrointestinal Solid TumorsPurpose
Researchers are studying combining RMC-6236 with other anti-cancer drugs in people with advanced digestive cancers (pancreatic, colorectal cancer, and others). The people in this study have either:
- Pancreatic cancer that has metastasized and has not yet been treated
- Colorectal cancer that has metastasized (spread) or is inoperable (cannot be removed with surgery)
RMC-6236 targets the protein made by a mutated (altered) form of the KRAS gene. The KRAS protein sends signals that cause cancer cells to grow. RMC-6236 is designed to prevent the KRAS protein from sending these signals. Blocking this action may slow or stop the growth of cancer cells. RMC-6236 is taken orally (by mouth).
Researchers hope that adding RMC-6236 to standard treatments is better than those therapies alone. If you join this study, you will get one of these treatments:
- RMC-6236 plus mFOLFIRINOX or FOLFOX (a combination of chemotherapy drugs) for some people with pancreatic or colorectal cancer
- RMC-6236 plus gemcitabine and nab-paclitaxel for some people with pancreatic or colorectal cancer
- RMC-6236 plus cetuximab, for people with colorectal or pancreatic cancer
- RMC-9805 plus mFOLFIRINOX or FOLFOX with or without RMC-6236 for some people with pancreatic or colorectal cancer
- RMC-9805 plus cetuximab with or without RMC-6236 for people with colorectal or pancreatic cancer
- RMC-9805 plus gemcitabine and nab-paclitaxel with or without RMC-6236 for some people with pancreatic or colorectal cancer
Who Can Join
To join this study, there are a few conditions. You must:
- Have metastatic pancreatic cancer that has not yet been treated, OR
- Have metastatic or inoperable colorectal cancer that has a mutation (change) in the RAS gene.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Wungki Park’s office at 646-888-4543.